2008/7/21 Roche Genentech、Roche の買収提案を拒否
Roche makes offer to acquire all outstanding shares of Genentech for US$89.00 per share in cash
Roche, a world-leading healthcare company, announced today that it has proposed to acquire the outstanding publicly held interest in Genentech, a leading biotechnology company, for US$89.00 per share in cash, or a total payment of approximately US$43.7 billion to equity holders of Genentech other than Roche. Roche acquired a majority in Genentech in 1990 and currently owns 55.9% of all outstanding shares.
Genentech Special Committee of Independent Directors Responds to Roche Proposal
The special committee of the Board of Directors of Genentech, Inc. announced that, after careful consideration, it has unanimously concluded that Roche's proposal to acquire the shares of Genentech not owned by Roche for $89.00 per share substantially undervalues the company. Therefore, the special committee does not support the proposal. However, the special committee would consider a proposal that recognizes the value of the company and reflects the significant benefits that would accrue to Roche as a result of full ownership.
Dr. Charles A. Sanders, chairman of the special committee, said, "The special committee is confident in the company's strong financial and clinical momentum and its uniquely productive R&D capabilities, which will continue to enhance shareholder value. In addition, we look forward to the company maintaining its successful relationship with Roche, regardless of ownership structure."
In light of the tremendous importance of Genentech's employees to the company's success, the special committee has approved the implementation of a broad-based employee retention program to address any employee concerns created by the Roche proposal. Genentech's Board of Directors, including the Roche representatives, had previously granted the special committee authority to implement such a program.
会長兼社長兼CEO Arthur D. Levinson
株式 公開／ニューヨーク証券取引所 DNA
参考 2008/2/11 武田発表、アムジェンと提携
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
Roche and Genentech announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The special committee of Genentech’s Board of Directors has approved the agreement and recommends that Genentech shareholders tender their shares in Roche’s tender offer.
Roche expects the combination to generate annual pre-tax cost synergies of approximately US$750 to $850 million. Synergies will be largely driven by reducing complexity and eliminating duplicative functions and processes in areas like late stage development, manufacturing, corporate administration and support functions. Savings resulting from this combination will enable the new company to increase and better focus its investment in innovation.